Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Electroporation Potentiated Immunotherapy in Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE1
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
- Status
- TERMINATED
- Phase
- PHASE2
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE2
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2